This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
|
|
- Ariel Harrington
- 5 years ago
- Views:
Transcription
1 This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. GROWTH HORMONE THERAPY POLICY Omnitrope is the EXCLUSIVE growth hormone covered if patient meets criteria. COVERAGE POLICY Growth hormone must be prescribed by a certified endocrinologist or pediatric nephrologist; growth hormone is considered medically necessary for treatment of members in the following diagnostic categories who meet the following criteria: Growth Hormone Deficiency in Children and Adolescents 1. Growth Hormone Deficiency Covered for children and adolescents with growth hormone deficiency (GHD) and growth failure who meet ALL of the following criteria: a. Patient has failed to respond to at least 2 standard GH stimulation tests, defined as a serum GH level (peak level) of < 10 ng/ml, after stimulation with insulin, levodopa, arginine, propranolol, clonidine or glucagon. However, one abnormal GH test is sufficient for children with brain tumors and irradiation with documented multiple pituitary hormone deficiency (MPHD); b. Appropriate imaging (MRI or CT) of the brain to exclude tumor on hypothalamic-pituitary region; c. One of the following criteria are met: i. Child has severe growth retardation with height standard deviation score (SDS) more than 3 SDS below the mean for ii. Child has moderate growth retardation with height SDS between -2 and -3 SDS below the mean chronological age and sex and decreased growth rate (growth velocity measured over one year below 25 th percentile for age and sex); OR iii. Child exhibits severe deceleration in growth rate (growth velocity measured over 1 year 2 SDS iv. COVERAGE POLICY below the mean for age and sex); OR Child has decreasing growth rate combined with a predisposing condition such as previous cranial irradiation or tumor; OR v. Child exhibits evidence of other pituitary hormone deficiencies or signs of congenital GHD (hypoglycemia, microphallus) 2. Chronic Renal Insufficiency Covered for children with chronic renal insufficiency and growth retardation awaiting renal transplantation who meet ALL the following criteria: a. Child s nutritional status has been optimized, metabolic abnormalities have been corrected and steroid usage has been reduced to a minimum; One of the following criteria are met: i. Child has severe growth retardation with height SDS more than 3 SDS below the mean for ii. Child has moderate growth retardation with height SDS between -2 and 3 SDS below the mean for chronological age and sex and decreased growth rate (growth velocity measured over one year below 25 th percentile for age and sex); OR Coventry Health Care, Inc. Page 1
2 iii. Child exhibits severe deceleration in growth rate (growth velocity measured over one year 2 SDS below the mean for age and sex) Growth hormone should be stopped after renal transplantation. 3. Turner s Syndrome Covered for girls with Turner s Syndrome and growth retardation who meet ALL the following criteria: a. The diagnosis of Turner s Syndrome is confirmed by chromosome analysis; b. One of the following criteria are met: i. Child has severe growth retardation with height SDS more than 3 SDS below mean for ii. Child has moderate growth retardation with height SDS between 2 and 3 SDS below the mean for chronological age and sex and decreased growth rate (growth velocity measure over one year below 25 th percentile for age and sex); OR iii. Child exhibits severe deceleration in growth rate (growth velocity measured over one year 2 SDS below mean for age and sex). 4. Short-Stature Homeobox-Containing Gene (SHOX) Deficiency: Covered for children with SHOX deficiency and growth retardation who meet ALL the following criteria: a. The diagnosis of SHOX deficiency is confirmed by appropriate chromosome analysis; b. One of the following criteria are met: i. Child has severe growth retardation with height SDS more than 3 SDS below mean for ii. Child has moderate growth retardation with height SDS between 2 and 3 SDS below the mean for chronological age and sex and decreased growth rate (growth velocity measure over one year below 25 th percentile for age and sex); OR iii. Child exhibits severe deceleration in growth rate (growth velocity measured over one year 2 SDS below mean for age and sex). 5. Prader Willi Syndrome Covered for children with Prader Willi Syndrome and growth retardation who meet ALL the following criteria: a. The diagnosis of Prader Willi Syndrome is confirmed by appropriate genetic testing, b. The patient has been evaluated for signs of severe respiratory impairment, upper airway obstruction, and sleep apnea before initiation of treatment, and will be routinely monitored for signs of respiratory infection during treatment, c. The patient is not severely obese prior to initiation of GH (ABW <200% above IBW), and an effective weight control program will be in place during treatment with GH, d. At least one (1) of the following criteria are met: i. Child has severe growth retardation with height SDS more than 3 SDS below mean for ii. Child has moderate growth retardation with height SDS between 2 and 3 SDS below the mean for chronological age and sex and decreased growth rate (growth velocity measure over one year below 25 th percentile for age and sex); OR iii. Child exhibits severe deceleration in growth rate (growth velocity measured over one year 2 SDS below mean for age and sex) 6. Small for Gestational Age (SGA) Children Covered for children born small for gestational age (defined as a birth weight < 2,500 g at a gestational age of more than 37 weeks or birth weight or length < 3 rd percentile for gestational age See Appendix I) who meet ALL the following criteria: a. Child with birth weight or length 2 or more standard deviations below the mean gestational age; b. Child fails to manifest catch up growth by age 3 years, defined as height 2 or more standard deviations below mean for age and sex. Coventry Health Care, Inc. Page 2
3 Review must include evaluation of growth curves from birth to age Noonan Syndrome Covered for children with Noonan Syndrome and growth retardation who meet ALL the following criteria: a. The diagnosis of Noonan Syndrome confirmed by appropriate genetic testing; b. One of the following criteria are met: i. Child has severe growth retardation with height SDS more than 3 SDS below mean for ii. Child has moderate growth retardation with height SDS between 2 and 3 SDS below the mean for chronological age and sex and decreased growth rate (growth velocity measure over one year below 25 th percentile for age and sex); OR iii. Child exhibits severe deceleration in growth rate (growth velocity measured over one year 2 SDS below mean for age and sex). 8. Idiopathic Short Stature (ISS) (only applicable to members insured by a Coventry benefit in the State of Maryland) ISS *additional criteria for members insured by a Coventry benefit in the State of Maryland. *Alternate Criteria for ISS GH therapy as presented by the Lawson Wilkins Pediatric Endocrine Society (LWPES) A trial of GH therapy will be approved for children with otherwise unexplained short stature who pass GH stimulation tests, but who meet most (3/5) of the following criteria: i. Height >2.25 SD below the mean for age or > 2 SD below the mid-parental height percentile; ii. Growth velocity < 25th percentile for bone age; iii. Bone age > 2 SD below the mean for age; iv. Low serum insulin-like growth factor 1 (IGF-1) and/or insulin-like growth factor binding protein 3 (IGFBP-3); v. Other clinical features suggestive of GHD. Growth Hormone Deficiency in Adults 1. Growth hormone deficiency Covered for replacement of endogenous growth hormone in patients with adult GH deficiency who meet ALL the following criteria: a. Adult onset: Patients who have growth hormone deficiency either alone or with multiple hormone deficiencies (hypopituitarism), as a result of EITHER, disease of the pituitary or hypothalamus, OR, injury to either the pituitary or hypothalmus from surgery, radiation therapy, or trauma; OR Childhood onset: Patients who were growth-hormone deficient during childhood who have GH deficiency confirmed as adult before replacement therapy is started. b. Biochemical diagnosis of GH deficiency, by means of a negative response to two standard GH stimulation test [maximum peak < 5 ng/ml when measured by RIA (polyclonal antibody) or < 2.5 ng/ml when measured by IRMA (monoclonal antibody)]. c. Patients already receiving full supplementation of other deficient hormones as required d. Objective measurement of clinical features of growth hormone deficiency: i. Severely decreased QOL (defined as score of at least 11 out of 25) as assessed using the Adult growth hormone deficiency assessment (AGHDA) questionnaire (see Appendix I); ii. EITHER, Reduced bone density of more than 1 SD below the age and gender-specific mean, (which by WHO criteria would predict a relative fracture risk of more than 2.5) provided that other etiologies have been ruled out or maximally treated; Coventry Health Care, Inc. Page 3
4 OR, Evidence of cardiac decompensation defined as reduced ejection fraction of < 50% provided that other etiologies have been ruled out or maximally treated; e. Growth hormone is initiated at a low dose and titrated slowly upward at monthly interval: i. Usual starting dose for adult onset is between 0.1 and 0.3 mg/day, with titration up to mg/day for male and titration up to mg/day for female; OR ii. Usual starting dose for childhood onset (transition patient) is between 0.4 and 0.8 mg/day, with titration up to mg/day. 2. AIDS related wasting Covered for HIV infected persons who meet ALL the following criteria: a. Involuntary weight loss of > 10% of pre-illness baseline body weight or body mass index (BMI) < 20 kg/m 2, in the absence of a concurrent illness or medical condition other than HIV infection that may cause the weight loss; b. Failed to adequately respond to or are intolerant to anabolic steroids (eg. Megace); c. Been on anti-retroviral therapy for greater than 30 days prior to beginning growth hormone treatment and will continue anti-retroviral therapy throughout treatment AUTHORIZATION PERIOD LIMITATIONS Growth Hormone Deficiency in Children and Adolescents Initial Approval: 6 months Extended Approval: Annual review is required to determine if growth hormone therapy continues to be medically necessary. The annual review should focus on: Response to therapy, Whether discontinuation criteria are met (see below), Whether there are any major changes in clinical status affecting the need for growth hormone therapy, Verification that the member is still under appropriate reevaluations and care of the network provider. Note: As growth velocity begins to slow down OR when the current height is within 3 inches of the target height based on mid-parental height calculation, review must be done every 6 months, using the annual review criteria. Growth Hormone Deficiency in Adults Initial Approval: 6 months Extended Approval: Biannual review (every 6 months) is required to determine if growth hormone therapy continues to be medically necessary. The biannual review should focus on: Evidence of compliance with recommended therapy, Response to therapy, Tolerability of therapy, Whether there are any major changes in clinical status affecting the need for growth hormone therapy, Verification that the member is still under appropriate reevaluations and care of the network provider, (AT THE 12 MONTH EVALUATION ONLY) Whether discontinuation criteria are met (see below) AIDS-related Wasting One Time Approval: 6 months Coventry Health Care, Inc. Page 4
5 PROCUREMENT Specialty pharmacy source: Aetna Specialty Pharmacy (ASRx) Contact: ASRx toll free number: (866) ASRx toll free fax number: (866) ASRx address: DISCONTINUATION OF THERAPY Growth Hormone Deficiency in Children and Adolescents In children and adolescents, growth hormone therapy is considered NOT medically necessary and is NOT covered if any of the following discontinuation criteria is met: a. Increase in height velocity < 2 cm total growth in one year of therapy; OR b. Expected final adult height, or target height based on mid-parental height calculation, or current absolute height 25th percentile* (defined as 68 inches in males and 63 inches in females), whichever has been reached first; OR c. Evidence of epiphyseal closure; OR d. Poor response to treatment, defined as an increase in growth velocity of less than 50% from baseline, in the first year of therapy. In children with Prader Willi Syndrome, evaluation of response to therapy should also take into account whether body composition (ie. ratio of lean to fat mass) has significantly improved; OR e. Persistent and uncorrectable problems with adherence to treatment, OR f. In children with Prader Willi Syndrome, patient shows signs of severe respiratory impairment, upper airway obstruction (including onset of or increased snoring) and/or new onset sleep apnea. Note: *Use of growth hormone after the absolute height has reached at least 25th percentile is considered cosmetic and therefore NOT covered. Growth Hormone Deficiency in Adults In adults, growth hormone therapy is considered NOT medically necessary and is NOT covered if any of the following discontinuation criteria are met following the first 12 months of treatment: a. No significant improvement in QOL, defined as less than a 7-point improvement compared to pre-treatment score, as assessed using the Adult growth hormone deficiency assessment (AGHDA) questionnaire; OR (Depending on which of the following applied to initiation of treatment) EITHER, b. No significant improvement of bone density at 12 months relative to pre-treatment measurement (defined as failure to achieve 5% increase in bone density; every -1 SD equals a 10 to 12% decrease in bone density), OR c. No significant improvement of cardiac function at 12 months relative to the pre-treatment measurement (defined as failure to improve the ejection fraction by 10%) NON-COVERAGE Growth hormone therapy is considered experimental/investigational and/or considered cosmetic benefit exclusion and/or NOT medically necessary and is NOT covered for the following conditions: a. Constitutional delay of growth and development b. To promote growth of infants or children with intrauterine growth retardation (except SGA as defined in the coverage criteria above) or Russell-Silver syndrome c. Skeletal dysplasias (eg. achondroplasia) d. Osteogenesis imperfecta e. Down Syndrome and other syndromes associated with short stature and malignant diathesis (eg. Bloom Syndrome, Fanconi Syndrome) f. Somatopause in older adults g. Infertility h. Chronic catabolic states, including respiratory failure, pharmacologic glucocorticoid administration, inflammatory bowel disease and short gut syndrome i. Burn injuries Coventry Health Care, Inc. Page 5
6 j. Obesity k. Hypophosphatemic rickets l. Muscular dystrophy m. Cystic fibrosis n. Noonan Syndrome without short stature o. Spina bifida p. Juvenile rheumatoid arthritis q. Osteoporosis, including osteoporosis related to menopause r. Post-traumatic stress disorder s. Depression t. Hypertension u. Corticosteroid-induced pituitary ablation v. Muscle mass preservation w. Any other genetic diagnoses associated with short stature x. Idiopathic short stature (non GH-deficient short stature) y. Treatment of GHD in children with Prader Willi Syndrome who are obese, have a history of upper airway obstruction or sleep apnea, and/or have severe respiratory impairment. This policy applies to all Coventry members unless superseded by applicable law. PROCEDURE Growth Hormone Therapy must be prior authorized by the Health Plan. Note: In Health Plan(s) where growth hormone coverage is excluded from the benefit, the benefit exclusion will supersede or override any conflicting portion of this Growth Hormone Therapy Policy. APPENDIX I: Fetal-Infant Growth corresponding to Gestational Age Tenth percentile of birth weight (g) for gestational age by gender: United States, 1991, single live births to resident mothers Gestational age, weeks Male Female Coventry Health Care, Inc. Page 6
7 Reprinted with permission from the American College of Obstetricians and Gynecologists (Obstetrics and Gynecology, 1996; 87:163). Coventry Health Care, Inc. Page 7
8 APPENDIX II: AGHDA Scores The AGHDA Questionnaire asks you to say 'yes' if any of the following 25 statements applies to you. Each 'yes' scores 1 point; the higher the score the worse the quality of life. 1. I have to struggle to finish jobs. 2. I feel a strong need to sleep during the day. 3. I often feel lonely even when I am with other people. 4. I have to read things several times before they sink in. 5. It is difficult for me to make friends. 6. It takes a lot of effort for me to do simple tasks. 7. I have difficulty controlling my emotions. 8. I often lose track of what I want to say. 9. I lack confidence. 10. I have to push myself to do things. 11. I often feel very tense. 12. I feel as if I let people down. 13. I find it hard to mix with people. 14. I feel worn out even when I've not done anything. 15. There are times when I feel very low. 16. I avoid responsibilities if possible. 17. I avoid mixing with people I don't know well. 18. I feel as if I'm a burden to people. 19. I often forget what people have said to me. 20. I find it difficult to plan ahead. 21. I am easily irritated by other people. 22. I often feel too tired to do the things I ought to do. 23. I have to force myself to do all the things that need doing. 24. I often have to force myself to stay awake. 25. My memory lets me down. REFERENCES 1. Gharib H, Cook DM, et.al. American association of clinical endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children update. Endocrine Practice, 2003; 9(1): Cook DM, Yuen KC, et. at. American association of clinical endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients update. Endocrine Practice, 2009; 15(Suppl 2): Richmond EJ, Rogol AD. Diagnosis of growth hormone deficiency in children. UpToDate www. uptodate.com. Accessed on 02/09/ Growth hormone deficiency. MedlinePlus Accessed on 02/09/ Growth failure in children with kidney disease. National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC) Accessed on 02/15/ Tönshoff, B. Growth hormone treatment in children with chronic kidney disease. UpToDate Accessed on 02/15/ Scheimann AO. Clinical features, diagnosis, and treatment of Prader-Willi syndrome. UpToDate Accessed 02/16/ Mandy, G. Small for gestational age infant. UpToDate. Accessed on 02/09/ Snyder, P. Growth hormone deficiency in adults. UpToDate. Accessed on 02/09/ Growth hormone in the treatment of HIV-associated wasting. US National Institute of Health Accessed 02/16/10. Coventry Health Care, Inc. Page 8
9 11. Schambelan M., Mulligan K., et.al. Recombinant human growth hormone in patients with HIVassociated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Annals of Internal Medicine Dec 1; 125(11): Short stature. MedlinePlus ttp:// Accessed on 02/09/ Alexander G., Himes J, et.al. A United States national reference for fetal growth. Obstetrics and Gynecology. 1996; 87: Fenton TR. A new growth chart for preterm babies: Babson and Benda's chart updated with recent data and a new format. BMC Pediatrics 2003, 3: AGHDA Scores. Pituitary Foundation Accessed on 02/15/ Goldstone AP, Holland AJ, et al., Recommendations for the diagnosis and management of Prader-Willi Syndrome. J Clin Endocrinol Metab, 2008, 93(11): Accessed 7/13/ Prader-Willi Syndrome Association. Growth Hormone Treatment and Prader-Willi Syndrome Clinical Advisory board Consensus Statement, 2009 Accessed 7/13/ Gunay-Aygun M, Schwartz S, et al., The changing purpose of prader-willi Syndrome Clinical Diagnostic Criteria and Proposed Revised Criteria. Pediatrics 2001, 108(5)92 Accessed 7/13/ Mahan JD, Warady BA. Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement. Pediatric Nephrology, 2006; 26: Accessed 7/13/ Growth hormone in chronic renal disease. Indian Journal of Endocrinology and Metabolism, 2012; 16:2 Accessed 7/13/ Guest G, Berard E, et al. Effects of growth hormone in short children after renal transplantation. French Society of Pediatric Nephrology. Pediatric Nephrology 1998; 12: Accessed 7/13/ Fine RN, Stablein D, et al. Recombinant human growth hormone post-renal transplantation in children: a randomized controlled study of the NAPRTCS Kidney Int 2002, 62: Accessed 7/13/ Vimalachandra D, Craig JC, et al. Growth hormone treatment in children with chronic renal failure: a meta-analysis of randomized controlled trials. J Pediatr 1998, 139: Accessed 7/13/12 Disclaimer: Coventry Health Care, Inc. (CHC) medical policies, technology assessments, and medical reviews (collectively CHC Policies ) are developed by CHC to provide guidance in administering plan benefits and constitute neither offers of coverage nor medical advice. Access to CHC Policies is provided for general reference purposes only and does not infer guaranteed coverage. CHC does not provide health care services or supplies. Providers are expected to exercise their independent medical judgment in rendering the most appropriate care. State and federal law, as well as benefit plan terms and conditions and CHC Policies in effect on the date that any service is rendered, including but not limited to definitions and specific inclusions/exclusions, take precedence over clinical policy and must be considered first in determining eligibility for coverage. The terms of the member's benefit plan shall determine coverage. Some benefit plans exclude coverage for services or supplies that Coventry may consider medically necessary. If there is a discrepancy between this policy and a member's benefit plan, the benefit shall govern. Coverage may also differ for CHC Medicare and/or Medicaid members based on any applicable Centers for Medicare & Medicaid Services (CMS) coverage statements including National Coverage Determination (NCD), Local Medical Review Policies (LMRP), and/or Local Coverage Determinations (LCD). As clinical technology is continually updated, CHC policies are subject to periodic updates. Do not rely on printed versions of CHC policies as they may be outdated. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or means without the written consent of CHC. Coventry Health Care, Inc. Page 9
Aetna Better Health of Virginia
Genotropin Nutropin Serostim Zomacton Humatrope Omnitrope Zorbtive somatropin Norditropin Saizen General Criteria for Approval: Omnitrope vial formulation is the preferred Growth Hormone product; consideration
More informationGrowth Hormones DRUG.00009
Market DC Growth Hormones DRUG.00009 Override(s) Prior Authorization Quantity Limit Approval Duration WPM PAB Center: Thirty (30) day exception for recently expired (within the past 45 days) growth hormone
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents
Aetna Better Health 2000 Market Street, Suite 850 Philadelphia, PA 19103 AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents Revised April 2014 Growth
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Growth Hormone (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationRequest for Prior Authorization Growth Hormone (Norditropin
Request for Prior Authorization Growth Hormone (Norditropin, Nutropin/AQ ) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Growth Hormone require a
More informationHUMAN GROWTH HORMONE GENOTROPIN
Drug Prior Authorization Guideline HUMAN GROWTH HORMONE GENOTROPIN (somatropin) PA9728 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes Additional Information: Medicare
More informationGrowth Hormone Therapy
Growth Hormone Therapy Policy Number: Original Effective Date: MM.04.011 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/23/2014 Section: Prescription Drugs Place(s)
More informationCIGNA HealthCare Prior Authorization Form - Growth Hormone Medications -
Pharmacy Services Phone: (800)244-6224 Fax: (800)390-9745 CIGNA HealthCare Prior Authorization Form - Growth Hormone Medications - Notice: Failure to complete this form in its entirety may result in delayed
More informationGeneral Approval Criteria for ALL Growth Hormone agents: (ALL criteria must be met)
Growth Hormone Agents Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Page 1 of 7 Preferred Agents Somatropin Pen (Norditropin ) Somatropin Pen (Nutropin AQ ) Non-Preferred
More informationFirst Name. Specialty: Fax. First Name DOB: Duration:
Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:
More informationGenotropin, Norditropin, Nutropin, Nutropin AQ, Humatrope, Saizen,
Blue Cross Blue Shield of Vermont and The Vermont Health Plan Prior Approval Guidelines Human Growth Hormone Somatropin (Genotropin, Norditropin, Nutropin, Nutropin AQ, Humatrope, Serostim, Saizen, Zomacton/TevTropin,
More information2. Is the request for Humatrope? Y N [If no, skip to question 6.]
Pharmacy Prior Authorization AETA BETTER HEALTH FLORIDA Growth Hormone Agents This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date.
More informationPrior Authorization Criteria Form This form applies to Paramount Commercial Members Only. Non-Preferred Growth Hormone Products
Prior Authorization Criteria Form This form applies to Paramount Commercial Members Only Criteria: P0078 Approved: 3/2017 Reviewed: Non-Preferred Growth Hormone Products Complete/review information, sign
More informationPHARMACY POLICY STATEMENT Indiana Medicaid
DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Indiana Medicaid Zomacton (somatropin) Must
More informationCircle Yes or No Y N. [If yes, skip to question 30.] 2. Is this request for a child? Y N. [If no, skip to question 20.]
05/20/2015 Prior Authorization MERC CARE PLA (MEDICAID) Growth Hormone (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other SOMATROPIN HUMATROPE GENOTROPIN NORDITROPIN NORDITROPIN FLEXPRO NORDITROPIN NORDIFLEX NUTROPIN NUTROPIN AQ OMNITROPE SAIZEN ZOMACTON 02824 BRAND ZORBTIVE BRAND SEROSTIM
More informationPHARMACY POLICY STATEMENT Indiana Medicaid
DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Indiana Medicaid Norditropin (somatropin)
More informationGROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT
1. Medical Condition TUEC Guidelines GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT Growth Hormone Deficiency and other indications for growth hormone therapy
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below including FDA-approved
More informationATHLETES & PRESCRIBING PHYSICIANS PLEASE READ
ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti-Doping Agency International Standard for TUEs. The TUE application process
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 03/01/201804/01/2019 POLICY A. INDICATIONS The indications below including
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 12/30/201601/01/2018TBD03/01/2018 POLICY A. INDICATIONS The indications
More informationAETNA BETTER HEALTH Prior Authorization guideline for Growth Hormone Agents
AETNA BETTER HEALTH Prior Authorization guideline for Growth Hormone Agents Growth Hormone and related agents Formulary: Omnitrope vials Non-Formulary: Genotropin, Humatrope, Saizen, Serostim, Tev-Tropin,
More informationOriginal Effective Date: 7/5/2007
Subject: Recombinant Human Growth Hormone: PEDIATRIC_GENETIC DISEASES with Primary Effects on Growth Turner syndrome Noonan syndrome Prader-Willi syndrome SHOX mutations DISCLAIMER Original Effective Date:
More informationThis Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. INJECTABLE OSTEOPOSIS AGENTS SUBJECT Pharmacologic Agents: Bisphosphonates: Boniva IV (ibandronate) Reclast (zoledronic
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Zomacton (aka. Tev-Tropin)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.12 Subject: Growth Hormone Pediatric Page: 1 of 6 Last Review Date: September 15, 2016 Growth Hormone
More informationPharmacy Prior Authorization Growth Hormone- Clinical Guidelines
Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Saizen, Serostim, somatropin, Zorbtive, Zomacton I. Growth Hormone Deficiency in Children and Adolescents: Note: Provider must submit chart notes
More informationTEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: HUMATROPE, NUTROPIN AQ, OMNITROPE, SAIZEN
TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: HUMATROPE, NUTROPIN AQ, OMNITROPE, SAIZEN STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING Date: Prescriber First & Last Name:
More informationPolicy: Growth Hormones Reference Number: TCHP.PHAR.184 Effective Date: Last Review Date:
Policy: Growth Hormones Reference Number: TCHP.PHAR.184 Effective Date: 07.01.2018 Last Review Date: 04.13.2018 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy
More informationTEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: GENOTROPIN & NORDITROPIN Texas Children s Health Plan Only
TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: GENOTROPIN & NORDITROPIN Texas Children s Health Plan Only STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING Date: Prescriber First
More informationPharmacy Management Drug Policy
SUBJECT: Policy POLICY NUMBER: Pharmacy-18 EFFECTIVE DATE: 08/03 LAST REVIEW DATE: 9/24/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not
More informationGrowth Hormone!gents. WA.PHAR.50 Growth Hormone Agents
Growth Hormone!gents WA.PHAR.50 Growth Hormone Agents Background: Human growth hormone, also known as somatotropin, is produced in the anterior lobe of the pituitary gland. This hormone plays an important
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: December 8, 2017 Growth Hormone Adult
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: September 15, 2016 Growth Hormone
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: December 5, 2014 Growth Hormone Adult
More informationGrowth Hormone Therapy Guidelines: Clinical and Managed Care Perspectives
At a Glance Review Article Practical Implications e135 Author Information e144 Full text and PDF Growth Hormone Therapy Guidelines: Clinical and Managed Care Perspectives Susan R. Rose, MD; David M. Cook,
More informationClinical Policy: Somatropin (Recombinant Human Growth Hormone) Reference Number: CP.PHAR.55 Effective Date: 03/11 Last Review Date: 06/17
Clinical Policy: (Recombinant Human Growth Hormone) Reference Number: CP.PHAR.55 Effective Date: 03/11 Last Review Date: 06/17 Line of Business: Medicaid Revision Log See Important Reminder at the end
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 2016-8 Program Prior Authorization/Medical Necessity Medication Human Growth Hormone: Somatropin (Genotropin *, Humatrope *, Norditropin
More informationGrowth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka
Growth hormone therapy for short stature in adolescents Growth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka K K K Gamage,
More informationGrowth Hormone: Review of the Evidence
Drug Use Research & Management Program DHS Division of Medical Assistance Programs, 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Growth Hormone: Review of the Evidence
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
Program Number 2018 P 1039-8 Program UnitedHealthcare Pharmacy Clinical Pharmacy Programs Prior Authorization/Notification Human Growth Hormone, Growth Stimulating Products Medication Human Growth Hormone:
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Zomacton
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: September 20, 2018 Growth Hormone
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Mecasermin (Increlex) Reference Number: CP.PHAR.150 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important
More informationAPPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY
Page 1 Somatropin INITIAL APPLICATION - growth hmone deficiency in children Growth hmone deficiency causing symptomatic hypoglycaemia, with other significant growth hmone deficient sequelae (e.g. cardiomyopathy,
More informationThe development of a manageable medical
Developing a Rational Approach for the Use of Growth Hormone in npediatric Patients David Cook, MD; and Gary Owens, MD The development of a manageable medical policy that ensures appropriate use of recombinant
More informationGROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY ADULT
1. Medical Condition GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY ADULT Growth Hormone Deficiency and other indications for growth hormone therapy (adult). 2. Diagnosis A.
More informationATHLETES & PRESCRIBING PHYSICIANS PLEASE READ
ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti- Doping Agency International Standard for TUEs. The TUE application process
More informationDiagnosing Growth Disorders. PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health
Diagnosing Growth Disorders PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health Content Normal pattern of growth and its variation Using growth charts Interpreting auxological
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on the Approach to Pediatric Anemia and Pallor. These podcasts are designed to give medical students an overview of key
More informationClinical Standards for GH Treatment in Childhood & Adolescence.
Clinical Standards for GH Treatment in Childhood & Adolescence. The Clinical Standards for GH treatment have been produced by the Clinical Committee of the BSPED. They are evidence based where possible
More informationMonth/Year of Review: September 2013 Date of Last Review: September 2012
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationClinical Policy: Tesamorelin (Egrifta) Reference Number: MA.PHAR.109 Effective Date: 11/16
Clinical Policy: (Egrifta) Reference Number: MA.PHAR.109 Effective Date: 11/16 Last Review Date: 07/17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Human Growth Hormone Page 1 of 57 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Human Growth Hormone Pre-Determination of Services IS REQUIRED by the Member s
More informationGrowth promoting treatment: When discretion is the better part of value
Growth promoting treatment: When discretion is the better part of value David B. Allen, MD Professor of Pediatrics University of Wisconsin School of Medicine and Public Health Head of Division of Diabetes
More informationClinical Policy: Pasireotide (Signifor LAR) Reference Number: CP.PHAR.332 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Signifor LAR) Reference Number: CP.PHAR.332 Effective Date: 03.01.17 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the
More informationHow to approach a child with growth concern
How to approach a child with growth concern Alaa Al Nofal, MD Assistant Professor of Pediatrics Pediatric Endocrinology Sanford Children Specialty Clinic Nothing to disclose Disclosure Objectives To understand
More informationOriginal Effective Date: 7/5/2007
Subject: Recombinant Human Growth Hormone (somatropin)_adult Growth Hormone Deficiency GHD HIV/AIDS-associated wasting and cachexia Short Bowel Syndrome (SBS) Policy Number: MCP-004-D Review Dates: 4/28/2010,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Human Growth Hormone Page 1 of 44 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Human Growth Hormone Pre-Determination of Services IS REQUIRED by the Member s
More informationGrowth Hormone Deficiency and Related Diagnoses
Care1st Health Plan Arizona, Inc. Easy Choice Health Plan Harmony Health Plan of Illinois Missouri Care Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona OneCare (Care1st Health
More informationPHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 4/1/19 SECTION: DRUGS LAST REVIEW DATE: 2/21/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
GROWTH HORMONE THERAPY: Genotropin (somatropin) subcutaneous injection Humatrope (somatropin) subcutaneous injection Norditropin (somatropin) subcutaneous injection Nutropin AQ (somatropin) subcutaneous
More informationDISCLAIMER SUMMARY OF EVIDENCE/POSITION
Subject: Recombinant Human Growth Hormone Original Effective Date: 7/5/2007 (somatropin)_ PEDIATRIC Growth Hormone Deficiency Growth Failure in Children and Adolescents with Classic GHD [under 18 years]
More informationClinical Policy: Thryoid Hormones and Insulin Testing in Pediatrics Reference Number: CP.MP.154
Clinical Policy: Thryoid Hormones and Insulin Testing in Pediatrics Reference Number: CP.MP.154 Effective Date: 12/17 Last Review Date: 12/17 See Important Reminder at the end of this policy for important
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject: Somatropin Table of Contents Coverage Policy...1 General Background...9 Coding/Billing Information... 12 References... 12 Effective Date.. 01/15/2018 Next
More informationMEDICAL POLICY I. POLICY HUMAN GROWTH HORMONE MP POLICY TITLE POLICY NUMBER
g Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): March 25, 2014 Effective Date: June 1, 2014 I. POLICY Recombinant human growth hormone (GH) therapy may be considered medically
More informationClinical Policy: Pasireotide (Signifor LAR) Reference Number: CP.PHAR.332
Clinical Policy: (Signifor LAR) Reference Number: CP.PHAR.332 Effective Date: 03/17 Last Review Date: 02/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationTechnology appraisal guidance Published: 26 May 2010 nice.org.uk/guidance/ta188
Human growth hormone (somatropin) for the treatment of growth failure in children Technology appraisal guidance Published: 26 May 2010 nice.org.uk/guidance/ta188 NICE 2017. All rights reserved. Subject
More informationGrowth hormone therapy in a girl with Turner syndrome showing a large increase over the initially predicted ht of 4 5
Disorders of Growth and Puberty: How to Recognize the Normal Variants vs Patients Who Need to be Evaluated Paul Kaplowitz, M.D Pediatric Endocrinology. VCU School of Medicine Interpretation of Growth Charts
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: HIM.PA.51 Effective Date: 12/14 Last Review Date: 08/17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this policy for
More informationTRANSITIONING FROM A PEDIATRIC TO AN ADULT ENDOCRINOLOGIST CARLOS A. LEYVA JORDÁN, M.D. PEDIATRIC ENDOCRINOLOGIST
TRANSITIONING FROM A PEDIATRIC TO AN ADULT ENDOCRINOLOGIST CARLOS A. LEYVA JORDÁN, M.D. PEDIATRIC ENDOCRINOLOGIST DISCLOSURE No potential conflict of interest OBJECTIVES Review timing considerations for
More informationClinical Policy: Measurement of Serum 1,25-dihydroxyvitamin D
Clinical Policy: Reference Number: CP.MP.152 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Mecasermin Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5 References... 5 Effective Date... 5/15/2017 Next
More informationa. Childhood onset: secondary to Any of the following causes: the term Growth Hormone Deficiency.
Recombinant Human Growth Hormone (rhgh) [For the list of services and procedures that need preauthorization, please refer to www.mcs.com.pr. Go to Comunicados a Proveedores, and click Cartas Circulares.]
More informationClinical Guideline POSITION STATEMENT ON THE INVESTIGATION AND TREATMENT OF GROWTH HORMONE DEFICIENCY IN TRANSITION
Clinical Guideline POSITION STATEMENT ON THE INVESTIGATION AND TREATMENT OF GROWTH HORMONE DEFICIENCY IN TRANSITION Date of First Issue 01/04/2015 Approved 28/01/2016 Current Issue Date 28/01/2016 Review
More informationEffective September 30, 2011 Please refer to the Pharmacy policy for the new coverage criteria
Effective September 30, 2011 Please refer to the Pharmacy policy for the new coverage criteria Name of Policy: Growth Hormone and Insulin Like Growth Factor-1 (IGF-1) Analogues Policy #: 067 Latest Review
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Human Growth Hormone) Reference Number: CP.CPA.84 Effective Date: 11.16.16 Last Review Date: 05.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this
More informationGrowth and Puberty: A clinical approach. Dr Esko Wiltshire
Growth and Puberty: A clinical approach Dr Esko Wiltshire NOTHING TO DISCLOSE Why is this character short? Food Psychosocial factors Major Systems (+drugs) Genetic potential Perinatal Classical Hormones
More information4/23/2015. Pediatric Growth Hormone Deficiency: Identification, Diagnosis, & Management. Conflict of Interest. Objectives THANK YOU!
Pediatric Growth Hormone Deficiency: Identification, Diagnosis, & Management Kent Reifschneider, MD CHKD / EVMS Norfolk, VA Conflict of Interest Speaker bureau and advisor for Pfizer Board member of The
More informationCommittee Approval Date: January 19, 2015 Next Review Date: January 2016
Medication Policy Manual Policy No: dru126 Topic: Increlex, mecasermin Date of Origin: January 3, 2006 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: February
More informationJudith Ross, 1 Peter A. Lee, 2 Robert Gut, 3 and John Germak Introduction
Hindawi Publishing Corporation International Journal of Pediatric Endocrinology Volume 2010, Article ID 494656, 7 pages doi:10.1155/2010/494656 Research Article Factors Influencing the One- and Two-Year
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Human Growth Hormone) Reference Number: AZ.CP.PHAR.402 Effective Date: 09.12.18 Last Review Date: 09.12.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Actonel, Atelvia) Reference Number: CP.PMN.100 Effective Date: 03.01.18 Last Review Date: 02.19 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the
More informationRECOMBINANT GROWTH HORMONE
RECOMBINANT GROWTH HORMONE Policy Number: 2014D0021A Effective Date: October 1, 2014 Table of Contents: Page: Cross Reference Policy: POLICY DESCRIPTION 2 Not Available. COVERAGE RATIONALE/CLINICAL CONSIDERATIONS
More informationHuman Growth Hormone
Human Growth Hormone Policy Number: 5.01.06 Last Review: 10/2018 Origination: 10.2000 Next Review: 10/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for human growth
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Forteo) Reference Number: CP.PHAR.188 Effective Date: 11.15.17 Last Review Date: 02.19 Line of Business: Commercial* (Exchange Plans), HIM, Medicaid Coding Implications Revision Log See
More informationClinical Policy: Testosterone Pellet (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date:
Clinical Policy: (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date: 07.25.17 Last Review Date: 11.17 Line of Business: Commercial Coding Implications Revision Log See Important Reminder
More informationGrowth hormone in children (for growth hormone deficiency, Turner's syndrome, chronic renal failure and idiopathic short stature) Anthony D, Stevens A
Growth hormone in children (for growth hormone deficiency, Turner's syndrome, chronic renal failure and idiopathic short stature) Anthony D, Stevens A Record Status This is a critical abstract of an economic
More informationStatement of Medical Necessity
Y E A R S (somatropin [rdna origin] for injection) Statement of Medical Necessity See inside cover for a list of documentation to accompany the Omnitrope Statement of Medical Necessity (SMN). Documentation
More informationClinical Policy: Mifepristone (Korlym) Reference Number: CP.PHAR.101
Clinical Policy: (Korlym) Reference Number: CP.PHAR.101 Effective Date: 05/12 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationCorporate Medical Policy
Corporate Medical Policy Treatment for Severe Primary IGF-1 Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: treatment_for_severe_igf-1_deficiency 2/2006 7/2017 7/2018
More informationObesity in Children. JC Opperman
Obesity in Children JC Opperman Definition The child too heavy for height or length Obvious on inspection 10 to 20% over desirable weight = overweight More than 20% = obese Use percentile charts for the
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Pellet (Testopel) Reference Number: CP.PHAR.354 Effective Date: 08.01.17 Last Review Date: 11.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the
More informationClinical Policy: Implantable Hormone Pellets Reference Number: CA.CP.MP.507
Clinical Policy: Reference Number: CA.CP.MP.507 Effective Date: 1/12 Last Review Date: 7/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: rifaximin (Xifaxan) Reference Number: HIM.PA.68 Effective Date: 12/14 Last Review Date: 08/17 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important
More informationEffective Health Care Program
Comparative Effectiveness Review Number 23 Effective Health Care Program Effectiveness of Recombinant Human Growth Hormone (rhgh) in the Treatment of Patients With Cystic Fibrosis Executive Summary Background
More information